Common Contracts
9 similar Executive Employment Agreement contracts by Brooklyn ImmunoTherapeutics, Inc., HNR Acquisition Corp.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 1st, 2024 • HNR Acquisition Corp. • Crude petroleum & natural gas • Texas
This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered by and between HNR Acquisition Corp, a Delaware corporation (the “Company”), and Mark Williams, an individual residing in Fulshear, Fort Bend, County, Texas (“Executive”), must be approved by a majority of the Board of Directors of the Company in order to be binding upon the Company prior to the Effective Date of January 29, 2024 (the “Effective Date”). Each of the Company and Executive are a “Party,” and collectively, they are the “Parties.”
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • December 20th, 2023 • HNR Acquisition Corp. • Crude petroleum & natural gas • Texas
This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of the first date set forth on the signature page hereof, is entered by and between HNR Acquisition Corp, a Delaware corporation (the “Company”), and Dante Caravaggio, an individual residing in Katy, Texas (“Executive”), must be approved by a majority of the Board of Directors of the Company in order to be binding upon the Company prior to the Effective Date of December 18, 2023 (the “Effective Date”). Each of the Company and Executive are a “Party,” and collectively, they are the “Parties.”
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT BROOKLYN IMMUNOTHERAPEUTICS, INC.Executive Employment Agreement • May 31st, 2022 • Brooklyn ImmunoTherapeutics, Inc. • Pharmaceutical preparations • Delaware
This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of May 10, 2022, is entered by and between Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “Company”), and Andrew Jackson, an individual residing in Cardiff, California 92007 (“Executive”) and, except with respect to the amendment and restatement hereof contained in the Recitals (which are incorporated by reference and made an operative part of this Agreement), will become effective as of the date on which Executive commences his employment with the Company (the “Effective Date”). Each of the Company and Executive is a “Party,” and collectively, they are the “Parties.”
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT BROOKLYN IMMUNOTHERAPEUTICS, INC.Executive Employment Agreement • May 31st, 2022 • Brooklyn ImmunoTherapeutics, Inc. • Pharmaceutical preparations • Delaware
This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of May 10, 2022, is entered by and between Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “Company”), and Andrew Jackson, an individual residing in Cardiff, California 92007 (“Executive”) and, except with respect to the amendment and restatement hereof contained in the Recitals (which are incorporated by reference and made an operative part of this Agreement), will become effective as of the date on which Executive commences his employment with the Company (the “Effective Date”). Each of the Company and Executive is a “Party,” and collectively, they are the “Parties.”
EXECUTIVE EMPLOYMENT AGREEMENT BROOKLYN IMMUNOTHERAPEUTICS, INC.Executive Employment Agreement • September 23rd, 2021 • Brooklyn ImmunoTherapeutics, Inc. • Pharmaceutical preparations • New York
This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of the first date set forth on the signature page hereof, is entered by and between Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “Company”), and Dr. Roger Sidhu, an individual residing in Newbury Park, California 91320 (“Executive”) and will be effective as of September 20, 2021 (the “Effective Date”). Each of the Company and Executive are a “Party,” and collectively, they are the “Parties.”
EXECUTIVE EMPLOYMENT AGREEMENT BROOKLYN IMMUNOTHERAPEUTICS, INC.Executive Employment Agreement • July 19th, 2021 • Brooklyn ImmunoTherapeutics, Inc. • Pharmaceutical preparations • New York
This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of the first date set forth on the signature page hereof, is entered by and between Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “Company”), and Jay Sial, an individual residing in Coto De Caza, California 92679 (“Executive”) and will be effective as of July 15, 2021 (the “Effective Date”). Each of the Company and Executive are a “Party,” and collectively, they are the “Parties.”
EXECUTIVE EMPLOYMENT AGREEMENT BROOKLYN IMMUNOTHERAPEUTICS, INCExecutive Employment Agreement • June 21st, 2021 • Brooklyn ImmunoTherapeutics, Inc. • Pharmaceutical preparations • New York
This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of June 16, 2021, is entered by and between Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “Company”), and Sandra Gurrola (“Executive”) and will be effective as of June 21, 2021 (the “Effective Date”). Each of the Company and Executive are a “Party,” and collectively, they are the “Parties.”
EXECUTIVE EMPLOYMENT AGREEMENT BROOKLYN IMMUNOTHERAPEUTICS, INC.Executive Employment Agreement • June 10th, 2021 • Brooklyn ImmunoTherapeutics, Inc. • Pharmaceutical preparations • New York
This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of June 5, 2021, is entered by and between Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “Company”), and Kevin D’Amour, PhD (“Executive”) and will be effective as of June 28, 2021 (the “Effective Date”). Each of the Company and Executive are a “Party,” and collectively, they are the “Parties.”
EXECUTIVE EMPLOYMENT AGREEMENT BROOKLYN IMMUNOTHERAPEUTICS, INCExecutive Employment Agreement • April 7th, 2021 • Brooklyn ImmunoTherapeutics, Inc. • Pharmaceutical preparations • New York
This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of April 1, 2021, is entered by and between Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “Company”), and Howard Federoff (“Executive”) and will be effective as April 16, 2021 (the “Effective Date”). Each of the Company and Executive are a “Party,” and collectively, they are the “Parties.”
